Cannabidiol + prolonged exposure for PTSD: randomized pilot trial

Introduction and clinical context

The study Cannabidiol + prolonged exposure for PTSD: randomized pilot trial (PubMed · 2024) is part of the scientific research on the use of cannabinoids in ptsd.

In post-traumatic stress disorder (PTSD), cannabinoids — especially cannabidiol (CBD) — are investigated as a possible adjuvant to psychiatric and psychotherapeutic treatment, with attention to symptoms such as nightmares, anxiety and hypervigilance. Case series and pilot trials suggest benefit in some patients, but the evidence is still early. PTSD treatment is multidisciplinary and should be led by mental-health professionals.

Understanding what science shows about the use of cannabinoids in ptsd helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. Randomized pilot trial combining CBD with prolonged exposure therapy in PTSD. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In PTSD, the central hypothesis involves the role of the endocannabinoid system in the extinction of fear memories and in regulating the stress response, with CBD potentially facilitating these processes and reducing anxiety. Safety recommends a preference for CBD-rich formulations, since excess THC can worsen anxiety and dissociative symptoms. Attention is given to interactions with psychotropics and to use in people with psychiatric vulnerability. The cannabinoid is studied as an adjuvant — never a substitute — for psychotherapeutic and psychiatric treatment, under follow-up.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PubMed · 2024). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does CBD help in PTSD?

Early studies suggest benefit as an adjuvant (including for nightmares); the evidence is still preliminary.

Does cannabis replace therapy for PTSD?

No. Treatment is multidisciplinary; cannabinoids are studied as a possible complement.